US · USD
EW
Edwards Lifesciences Corp
- Day's range
- US$84.49 – US$86.84
- Day's volume
- US$262.8m
- 52-week range
- US$72.65 – US$95.18
Follow EW on Fuolio
See how EW weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountEW in numbers
- Market cap
- US$49.1bn
- P/E
- 48.86
- P/B
- 4.62
- Dividend yield (12m)
- 0.00%
- Net debt/EBITDA
- -2.26
EW trades at 48.86 times its earnings of the last 12 months.
EW price history
EW risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +10.99% | +24.60% | -23.75% |
| Volatility (annualised) | 18.00% | 27.67% | 29.35% |
| Largest drawdown | -7.60% | -34.02% | -51.33% |
| Positive months | 7/12 | 23/36 | 34/60 |
How much did investing in EW return?
US$1,000.00 invested on 01/09/2021 would be worth US$762.48 today.
- Value today in EW
- US$762.48
- Return over the period
- -23.75%
- Return per year
- -5.28%
- In the S&P 500
- US$1,776.31
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
EW fundamentals
Valuation
- P/E48.86
- P/B4.62
- EV/EBITDA28.15
- EV/EBIT31.37
- EV/Revenue6.98
- P/EBIT33.89
- P/S7.54
- P/OCF28.54
- P/FCF34.25
- Earnings yield3.19%
- PEG ratio—
- Earnings per shareUS$1.74
- Book value per shareUS$18.42
Debt
- Net debt-US$3.7bn
- Net debt/EBITDA-2.26
- Net debt/Equity-0.34
- Debt/Equity0.06
- Current ratio4.52
- Quick ratio3.77
- Cash ratio2.82
Efficiency
- Gross margin77.84%
- EBITDA margin24.79%
- Operating margin22.25%
- Net margin15.43%
- Asset turnover0.47
Profitability
- ROE9.46%
- ROA7.25%
- ROIC14.36%
- Payout0.00%
Growth
- Revenue CAGR (5 years)5.75%
- Earnings CAGR (5 years)—
- Revenue growth (year)—
- Earnings growth (year)—
- Revenue growth (quarter)—
- Earnings growth (quarter)—
What is EW's fair price?
Two classic value formulas, with today's numbers. The current price is US$85.19.
- Graham's fair price
- US$26.88
- 68.45% below the price
√(22.50 × US$1.74 × US$18.42)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- —
- Does not apply to EW: it paid no distributions in the last five years.
Décio Bazin only bought shares yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years divided by 6%.
Graham ignores growth and debt; Bazin assumes past distributions will repeat. They are reference points for comparison, not a buy recommendation.
EW indicators by year
Multiples at each year's closing price; margins and returns from that year's accounts.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E | 46.12 | 10.43 | 32.69 | 29.82 | 53.71 | — | — | — |
| P/B | 4.79 | 4.35 | 6.89 | 7.82 | 13.83 | 12.46 | 11.76 | 10.13 |
| EV/EBITDA | 32.30 | 26.17 | 30.82 | 27.33 | 43.76 | 55.90 | 38.72 | 38.11 |
| Earnings per share | US$1.85 | US$7.10 | US$2.33 | US$2.50 | US$2.41 | — | — | — |
| Book value per share | US$17.80 | US$17.01 | US$11.06 | US$9.55 | US$9.36 | US$7.32 | US$19.84 | US$15.12 |
| ROE | 10.38% | 41.75% | 21.09% | 26.21% | 25.76% | — | — | — |
| ROIC | 15.63% | 18.78% | 20.73% | 25.17% | 30.07% | 21.40% | 31.91% | 25.55% |
| Gross margin | 78.01% | 79.46% | 80.47% | 83.79% | 76.13% | 75.36% | 74.37% | 74.77% |
| EBITDA margin | 23.42% | 28.20% | 29.02% | 36.69% | 34.88% | 22.91% | 28.43% | 22.18% |
| Net margin | 17.69% | 76.75% | 27.99% | 34.09% | 28.73% | — | — | — |
| Net debt/EBITDA | -2.55 | -2.20 | -0.71 | -0.38 | -0.48 | -0.80 | -0.75 | -0.44 |
EW financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | US$6.1bn | US$5.4bn | US$5bn | US$4.5bn | US$5.2bn | US$4.4bn |
| Cost of sales | -US$1.3bn | -US$1.1bn | -US$978.4m | -US$723.7m | -US$1.2bn | -US$1.1bn |
| Gross profit | US$4.7bn | US$4.3bn | US$4bn | US$3.7bn | US$4bn | US$3.3bn |
| EBITDA | US$1.4bn | US$1.5bn | US$1.5bn | US$1.6bn | US$1.8bn | US$1bn |
| EBIT | US$1.3bn | US$1.4bn | US$1.3bn | US$1.5bn | US$1.7bn | US$897.6m |
| Net finance result | US$8.7m | US$169.4m | US$63.5m | US$21.1m | — | — |
| Profit before tax | US$1.3bn | US$1.5bn | US$1.4bn | US$1.5bn | US$1.7bn | US$916.7m |
| Income tax | -US$216.9m | -US$152.1m | -US$152.4m | -US$195.5m | -US$198.9m | -US$93.3m |
| Net income | US$1.1bn | US$4.2bn | US$1.4bn | US$1.5bn | US$1.5bn | — |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
Does EW pay dividends?
EW has no distributions on record.
About Edwards Lifesciences
- Sector
- Manufacturing
Questions about EW
How much is EW today?
EW is at US$85.19 (-1.31% on the day), last traded on 01/10/2026.
What are the P/E and P/B of EW?
EW trades at a P/E of 48.86 and a P/B of 4.62.
How much did EW return in 12 months?
EW returned 10.99% in 12 months, with annualised volatility of 18.00% and a largest drawdown of -7.60%.